BioNTech Results Presentation Deck
We expanded our base of strategic collaborators in 2020 to-date
CO
6
Covid-19 vaccine
50:50 Gross Profit share¹
Pfizer
FOSUNPHARMA
Collaborations for clinical stage programs
Bispecific mABs
50:50 Cost & Profit share
Fix Vac Melanoma
Each company to keep 100%
of rights to own product
REGENERON
Seasonal Influenza
Royalties & Milestones
Pfizer
iNeST
50:50 Cost & Profit share
Genentech
Pre-clinical Collaborations
Up to 10 Infectious
Disease Indications
Worldwide opt-in right
University of
Pennsylvania
150:50 Cost & Profit share refers to terms of Pfizer collaboration only (world-wide ex-China)
HIV, Tuberculosis
Developed world rights
BILL & MELINDA
Genmab
GATES foundation
Intra-tumoral mRNA
Cost & Profit share
SANOFI
5 Rare Disease
Indications
50:50 Cost & Profit share
GENEVANT
BIONTECHView entire presentation